1st fully AI designed drug for lung disease enters human clinical trials – ET HealthWorld
Hong KongInitially, a drug discovered and designed using artificial intelligence (AI) for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic disease that causes scarring of the lungs, has entered human clinical trials. Hong Kong-based biotech company Insilic medicine, in a statement, announced that the Phase II oral dosing trial of INS018_055 is currently running … Read more